<DOC>
	<DOC>NCT00511355</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the effects of the combined oral contraceptive (COC) NOMAC-E2 on hemostasis, lipids, carbohydrate metabolism, adrenal function, and thyroid function.</brief_summary>
	<brief_title>Effects on Hemostasis, Lipids, Carbohydrate Metabolism, Adrenal &amp; Thyroid Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing LNG-EE (292004)(COMPLETED)(P05764)</brief_title>
	<detailed_description />
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives, Oral, Combined</mesh_term>
	<criteria>Sexually active women, at risk for pregnancy and not planning to use during trial medication use; Women in need for contraception and willing to use an oral contraceptive (OC) for 6 months (6 cycles); At least 18 but not older than 50 years of age at the time of screening; Body mass index = 17 and = 29 kg/m^2; Good physical and mental health; Willing to give informed consent in writing Present use or use within 2 months prior to screening of any other hormonal treatment including sex hormones (other than contraceptives), insulin, thyroid and corticosteroid hormones (with the exception for local dermatological use); Contraindications for contraceptive steroids Presence or history (within 1 year before screening) of alcohol or drug abuse as judged by the (sub)investigator. An abnormal cervical smear (i.e.: dysplasia, cervical intraepithelial neoplasia [CIN], SIL, carcinoma in situ, invasive carcinoma) at screening or documentation of an abnormal smear performed within 6 months before screening; Clinically relevant abnormal laboratory result at screening as judged by the (sub) investigator; Use of an injectable hormonal method of contraception prior to screening; within 6 months of an injection with a 3 month duration, within 4 months to screening of an injection with a 2month duration, within 2 months of an injection with a 1month duration; Before spontaneous menstruation has occurred following a delivery or abortion; Breastfeeding or within 2 months after stopping breastfeeding prior to the start of trial medication; Present use or use within 2 months prior to the start of the trial medication of the following drugs: phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole, lipidlowering drugs, anticoagulants and herbal remedies containing Hypericum perforatum (St John's Wort); Use of pharmacological agents which affect the hemostatic system during the pretreatment blood sampling: vitamin K (only prohibited within two weeks prior to sampling), nonsteroidal antiinflammatory drugs (NSAIDS) and aspirin (both only prohibited during the week prior to sampling); Administration of investigational drugs and/or participation in another clinical trial within 2 months prior to the start of the trial medication or during the trial period.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>